Navigation Links
Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute
Date:1/28/2008

New York, New York The Cancer Research Institute (CRI) announced today that it has brought together the Cancer Vaccine Consortium, a program of the Sabin Vaccine Institute, and the Cancer Vaccine Collaborative, a program of the Cancer Research Institute (CRI) and the Ludwig Institute for Cancer Research (LICR), to form the leading initiative on cancer vaccines. This joint effort establishes a unified voice in the cancer vaccine field and provides a major new resource to academia, industry, and governmental agencies involved in cancer vaccine discovery and development.

The Cancer Vaccine Consortium, now administered by the Cancer Research Institute, is an international association of 67 pharmaceutical, biotechnology, and academic institutions engaged in cancer vaccine and immunotherapy research and development. The Cancer Vaccine Collaborative is a coordinated global network of 22 academic clinical and laboratory centers with strong immune monitoring capabilities and the capacity to conduct early-phase clinical trials.

Linking these programs under a single organization offers great synergism for academic and industrial collaboration and provides improved capabilities for all its members. Together, the two programs aim to address the needs of the immunotherapy community with the goal to accelerate discovery and development, and facilitate regulatory discussions about cancer vaccines and other immunotherapies.

The objectives and activities of the new Cancer Vaccine Consortium will encompass:

  • Hosting scientific conferences and workshops on cancer vaccines and other immunotherapies to facilitate knowledge exchange;
  • Forming alliances with academic and industrial organizations across the globe to further accelerate progress;
  • Facilitating ongoing dialogue with regulatory bodies to help develop needed standards for evaluating cancer immunotherapies;
  • Developing and standardizing methodologies for measuring the immune response to cancer vaccination and establishing surrogate biological markers for therapeutic benefits;
  • Managing the production and acquisition of reagents for clinical trials of cancer vaccines;
  • Continuing support of the existing international network of academic laboratory and clinical investigators conducting early-phase cancer vaccine trials aimed at learning how to effectively immunize against cancer.

Lloyd J. Old, M.D., chairman of the Ludwig Institute for Cancer Research, director of the Cancer Research Institute Scientific Advisory Council, and director of the CRI/LICR Cancer Vaccine Collaborative, will also serve as director of the CRI Cancer Vaccine Consortium and chairman of its Executive Committee. Axel Hoos, M.D., Ph.D., medical lead in Immuno-Oncology at Bristol-Myers Squibb Company and former president of the Sabin Vaccine Institutes Cancer Vaccine Consortium, will serve as co-chairman of the Cancer Vaccine Consortium Executive Committee.

The time is ripe for stronger alliances between academia and industry, says Dr. Old. Integrating the clinical trials network of the CRI/LICR Cancer Vaccine Collaborative with the strengths of the pharmaceutical, biotech, and academic membership of the Sabin Cancer Vaccine Consortium will allow the Cancer Research Institute to present a single, united front on cancer vaccines to the scientific and medical communities. This alignment strengthens the overall position of all of its participants and establishes a unified voice that can represent the needs of a broader constituency.

Dr. Hoos anticipates that the joint effort will play a key role in facilitating knowledge exchange and creating a fertile environment for advances in cancer immunotherapy. The Sabin Vaccine Institutes Cancer Vaccine Consortium had very successfully begun to address issues of clinical paradigm development, immune assay harmonization, and regulatory dialogue, Dr. Hoos says. Based on the Consortiums track record of bringing stakeholders together, identifying needs, and addressing them through focused initiatives, the alliance with CRI promises growth and delivery of further concrete solutions, which can be adopted widely.

The Cancer Research Institute has fostered the fields of immunology and tumor immunology over the past 54 years through the provision of research and training grants to academic investigators, and dedicates approximately 35 percent of its annual research budget to the support of cancer vaccine research. By incorporating the Sabin Vaccine Institutes Cancer Vaccine Consortium into the Cancer Research Institutes clinical investigation efforts, we are expanding CRIs reach and ability to deliver accelerated progress in this growing field, says Jill ODonnell-Tormey, Ph.D., executive director of the Cancer Research Institute. That should be very appealing to the Institutes donors who wish to make an impact on cancer with measurable outcomes that can be realized within a short period of time, she adds.


'/>"/>

Contact: Brian Brewer
bbrewer@cancerresearch.org
212-688-7515
Cancer Research Institute
Source:Eurekalert

Related medicine news :

1. Teens, Young Adults Missing Out on Latest Cancer Advances
2. Oral Contraceptives Cut Ovarian Cancer Risk
3. TNF-alpha antagonist stops inflammation-induced colon cancer in its tracks
4. New Colon Cancer Test Might Spot Trouble Earlier
5. Kroger Pink Tag Campaign Raises $137,500 for Breast Cancer Research and Awareness at Karmanos Cancer Institute
6. Synthesis of natural molecule could lead to better anti-cancer drugs
7. Engineers use bloods hydrodynamics to manipulate stem, cancer cells
8. Combination therapy improves survival for certain prostate cancer patients
9. Hormone Therapy Only Helps Some Older Men With Prostate Cancer
10. Cell division studies hint at future cancer therapy
11. Regular, long-term aspirin use reduces risk of colorectal cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... 21, 2017 , ... The Margarian Law Firm has filed a class ... ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand of ... Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is made ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing how to ... shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. To ... Kickstarter on Monday, July 21st. , The kit uses colorful, engaging and educational ...
(Date:7/21/2017)... CANADA (PRWEB) , ... July 21, 2017 , ... ... torn anterior cruciate ligament (ACL) offer patients improved quality of life five years ... for Sports Medicine’s Annual Meeting in Toronto, Ontario, Canada. The study followed ...
(Date:7/20/2017)... Boston, MA (PRWEB) , ... July 20, 2017 ... ... aggressive form of blood and bone marrow cancer that progresses rapidly without treatment. ... often recommended to reduce the chance of reoccurrence and relapse. With such ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... in which their iMedSecure™ comes included with each system installation. RMT’s iMedHD2™ ... to remote participants for real-time collaboration and immediate decision-making requirements. While never ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... 2017  New York City-based market research firm Kalorama Information ... aware of.  From new products to new costs, to the ... recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact Moment Arriving ... the impact the growing population and, to a more extreme ...
(Date:7/11/2017)... ROCKVILLE, Md. , July 11, 2017  The ... had estimated revenues of approximately $394.1 million in 2016.  ... a trend of solid growth, in particular as a ... oncology clinical practice, and the recent introduction of a ... the need for less-invasive testing of tumor biomarkers to ...
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
Breaking Medicine Technology: